Akita Biosciences is a biotech organization pioneering novel intranasal therapies that help people live healthy and vibrant lives. Akita’s lead product is a once-daily nasal spray that is taken proactively to help reduce the risk of common respiratory infections such as Influenza A, Influenza B, SARS-CoV-2, RSV, Adenovirus, E. coli, and K. Pneumonia. Our proprietary drug delivery platform creates a barrier that controls mucosal absorption and optimizes the residence time across a wide range of molecules and biologics.
